Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Humanetics Corporation

Humanetics Corporation to Present at Upcoming Military Medical and Defense Conferences
From Humanetics Corporation
Via Business Wire
Humanetics Corporation to Participate in Benchmark Healthcare Investor Conference This Week
From Humanetics Corporation
Via Business Wire
Humanetics Corporation Chief Medical Officer Is Featured Guest at U.S. Industry, National Security, and Healthcare Forum
From Humanetics Corporation
Via Business Wire
Humanetics Corporation Announces Positive Phase 2 Clinical Trial Results in COVID-19 Study Aimed at Improving Pulmonary Function
From Humanetics Corporation
Via Business Wire
Humanetics Secures Additional Funding to Advance Development of Its Drug to Prevent Radiation Injury
From Humanetics Corporation
Via Business Wire
Humanetics Advances Development of Novel Radiation Protection Drug With New Study Results
From Humanetics Corporation
Via Business Wire
Humanetics Corporation Presents at the 2024 Department of Defense Scientific Meeting
From Humanetics Corporation
Via Business Wire
Humanetics to Participate in the Bio Investor Forum in San Francisco
From Humanetics Corporation
Via Business Wire
Uniformed Services University Awards Grant to Support Continued Collaboration with Humanetics to Develop Radiation Countermeasure
From Humanetics Corporation
Via Business Wire
Humanetics Corporation to Present at the BIO International Convention in San Diego
From Humanetics Corporation
Via Business Wire
Humanetics Corporation to Present at Investor and Partnering Conferences
From Humanetics Corporation
Via Business Wire
Major General (Ret.) Barbara R. Holcomb Joins Board at Humanetics
From Humanetics Corporation
Via Business Wire
Humanetics Corporation Appoints Dr. Colin Chinn as Chief Medical Officer
From Humanetics Corporation
Via Business Wire
Humanetics Corporation Receives Funding to Study New Drug for Idiopathic Pulmonary Fibrosis
From Humanetics Corporation
Via Business Wire
Humanetics Corporation Publishes Positive Clinical Trial Results of BIO 300 in Patients with Non-Small Cell Lung Cancer
From Humanetics Corporation
Via Business Wire
Humanetics Corporation Awarded Contract From Department of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury
From Humanetics Corporation
Via Business Wire
BIO 300 Featured at the 2023 Military Health System Research Symposium
From Humanetics Corporation
Via Business Wire
BIO 300 Enhances Radiotherapy Efficacy Against Lung Tumors in a Nonclinical Model
From Humanetics Corporation
Via Business Wire
Humanetics Corporation Announces Positive Results from Independent Data Monitoring Committee Review of Phase 2 Clinical Trial
From Humanetics Corporation
Via Business Wire
BIO 300 Demonstrates Protection Against Radiation-Induced Lung Injury
From Humanetics Corporation
Via Business Wire
Humanetics Corporation Presents at the MedInvest Oncology Investor Conference
From Humanetics Corporation
Via Business Wire
Humanetics Corporation Publishes Phase 1 Trial Results for BIO 300 Oral Powder
From Humanetics Corporation
Via Business Wire
Humanetics Corporation Presents at the 68th Annual International Radiation Research Society Meeting
From Humanetics Corporation
Via Business Wire
Humanetics Receives FDA Clearance to Begin Studies in Second Oncology Indication
From Humanetics Corporation
Via Business Wire
Thomas F. Jasper Joins Board at Humanetics
From Humanetics Corporation
Via Business Wire
Jake R. Nunn Joins Board at Humanetics
From Humanetics Corporation
Via Business Wire
BIO 300 Pharmacokinetics Studies Published
From Humanetics Corporation
Via Business Wire
U.S. Department of Defense Awards $5.1 Million to Humanetics Corporation for Continued Development of Radiation Countermeasure
From Humanetics Corporation
Via Business Wire
Humanetics Corporation Expands Long-Haul COVID-19 Trial to Additional Sites
From Humanetics Corporation
Via Business Wire
New Studies Published Comparing BIO 300 to Neulasta® for Acute Radiation Syndrome
From Humanetics Corporation
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.